<!--
title:  Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants
description: DOI: 10.1021/acs.jnatprod.1c00946
published: true
date: 2022-01-21T13:14:44.746Z
tags: #covid19, #prevention, #sars-cov2, #cannabies, #cannabinoid, #cellular, #entry, #variants
editor: ckeditor
dateCreated: 2022-01-21T13:14:44.746Z
-->

<p>J Nat Prod</p>
<p>. 2022 Jan 10;acs.jnatprod.1c00946.</p>
<p>doi: 10.1021/acs.jnatprod.1c00946. Online ahead of print.</p>
<h1><strong>Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants</strong></h1>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/?term=van+Breemen+RB&amp;cauthor_id=35007072">Richard B van Breemen</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/35007072/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Muchiri+RN&amp;cauthor_id=35007072">Ruth N Muchiri</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/35007072/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Bates+TA&amp;cauthor_id=35007072">Timothy A Bates</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/35007072/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Weinstein+JB&amp;cauthor_id=35007072">Jules B Weinstein</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/35007072/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Leier+HC&amp;cauthor_id=35007072">Hans C Leier</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/35007072/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Farley+S&amp;cauthor_id=35007072">Scotland Farley</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/35007072/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Tafesse+FG&amp;cauthor_id=35007072">Fikadu G Tafesse</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/35007072/#affiliation-2"><sup>2</sup></a></p>
<p>Affiliations expand</p>
<ul>
  <li>PMID: <strong>35007072</strong></li>
  <li>PMCID: <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8768006/">PMC8768006</a></li>
  <li>DOI: <a href="https://doi.org/10.1021/acs.jnatprod.1c00946">10.1021/acs.jnatprod.1c00946</a></li>
</ul>
<h2><strong>Abstract</strong></h2>
<p>As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection-mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (<i>Cannabis sativa</i>) were found to be allosteric as well as orthosteric ligands with micromolar affinity for the spike protein. In follow-up virus neutralization assays, cannabigerolic acid and cannabidiolic acid prevented infection of human epithelial cells by a pseudovirus expressing the SARS-CoV-2 spike protein and prevented entry of live SARS-CoV-2 into cells. Importantly, cannabigerolic acid and cannabidiolic acid were equally effective against the SARS-CoV-2 alpha variant B.1.1.7 and the beta variant B.1.351. Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2.</p>
<p>&nbsp;</p>
<p>Source: https://pubmed.ncbi.nlm.nih.gov/35007072/</p>
